Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
boston top stories
deals
gilead sciences
indiana blog main
indiana top stories
novartis
startups
alzheimer's disease
amgen
astrazeneca
biogen
cancer
cancer immunotherapy
covid-19
crispr
What
bio
5
×
ceo
5
×
roundup
acquisitions
biggest
big
company
crispr
daniel
drug
gilead
medicine
moves
o’day
sciences
today
week
world’s
according
akin
albert
announced
blood
bosley's
bosley’s
bourla
bridge
bucks
build
buy
cas
collabs
company’s
covid
create
crime
crowdsourced
deal
debut
departure
Language
unset
unknown
Current search:
bio
×
ceo
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@techcrunch.com
7 years ago
Regenerative medicine today is like the internet in 1993
